Biotechnology News – including medical research, studies, human genome, bio-technology devices and services news, as issued by the Send2Press Newswire service.
| From: Neurotech Reports
NEW YORK, N.Y., March 5, 2026 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Ninth Annual Bioelectronic Medicine Forum will take place on April 14, 2026. The one-day event will be held at the New York Academy of Medicine in Manhattan.
| From: HLA Protein Technologies Inc.
OKLAHOMA CITY, Okla., Nov. 19, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) today announced the commercial launch of its new soluble HLA-G (sHLA-G) product portfolio, marking an expansion of its next-generation HLA research tools. HLA-G is a non-classical MHC Class I molecule recognized as a key immune checkpoint regulator.
| From: HLA Protein Technologies Inc.
OKLAHOMA CITY, Okla., Sept. 30, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) reports that its new manufacturing expansion is positioned to support the Company’s growth. A new product line launch, a strategic investment led by a private investor group; and a corporate rebrand to HLA Protein Technologies, reflects the company’s expanded focus on advanced immunology and oncology research tools.
| From: Neurotech Reports
SAN FRANCISCO, Calif., Aug. 11, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that two prominent figures in the field of neurotechnology will keynote the 2025 Neurotech Leaders Forum, which takes place November 5-6 in San Francisco. Edward Chang, chair of the department of neurological surgery at UC San Francisco, will discuss future applications of implanted brain sensing and stimulation devices.
| From: Zeteo Biomedical LLC
CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled “Cartridge Devices for Administration of a Medicament” (U.S. Patent No. 12329949) and “Hand-Operated Devices for Administration of a Medicament” (EU Patent No. 3946526), further strengthen Zeteo’s ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes.
| From: Amerigo Scientific
NEW YORK, N.Y., May 9, 2025 (SEND2PRESS NEWSWIRE) — Amerigo Scientific unveils its line of different-sized bioconjugated fluorescent nanodiamonds (FNDs), designed to redefine precision in cellular and in vivo imaging. These bioconjugated FNDs are provided to address critical challenges in high-resolution diagnostics, targeted drug delivery, and real-time biological tracking, positioning itself as a game-changer for researchers and scientists alike.
| From: Redox Therapeutics Inc.
PHILADELPHIA, Pa., April 29, 2025 (SEND2PRESS NEWSWIRE) — Redox Therapeutics announces the signing of an exclusive license agreement with The Curators of the University of Missouri acting by and through the Missouri University of Science and Technology (Missouri S&T) for a patented polymer nanoparticles technology designed for endotoxin removal from fluids such as water, protein solutions and plasma.
| From: Neurotech Reports
SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, “The Market for Implanted Pain Neuromodulation Systems: 2025-2030,” the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate.
| From: Neurotech Reports
NEW YORK, N.Y., March 17, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Eighth Annual Bioelectronic Medicine Forum will take place on April 10, 2025. The one-day event will be held at the New York Academy of Medicine in Manhattan.
| From: Neurotech Reports
SAN FRANCISCO, Calif., Jan. 30, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the longest-serving publishing and market intelligence firm covering the neuromodulation industry, announced the launch of its first European management and investment conference. The two-day event, called Neurotech Leaders Forum at imec, will take place on June 3-4, 2025 on the campus of imec in Leuven, Belgium. Imec, a world-leading research and innovation center in nanoelectronics and digital technologies, is deeply committed to advancing health innovations through the power of semiconductor technologies, making it the ideal host for the conference.
| From: Neurotech Reports
NEW YORK, N.Y., March 19, 2024 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024. The one-day event will be held at the New York Academy of Medicine in Manhattan.
| From: Divergent CRO
ATLANTA, Ga., Feb. 1, 2024 (SEND2PRESS NEWSWIRE) — Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.
| From: BioAustinCTX
AUSTIN, Texas, Feb. 1, 2024 (SEND2PRESS NEWSWIRE) — BioAustinCTX, Central Texas’ Life Science industry organization, announced today the appointment of Cindy WalkerPeach, PhD and Ryan Hawkins to its Board of Directors. BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region.
| From: Neurotech Reports
SAN FRANCISCO, Calif., Oct. 31, 2023 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.
| From: Neo-Bionica
LOS ANGELES, Calif., Sept. 25, 2023 (SEND2PRESS NEWSWIRE) — Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica’s technology division spearheading its mission to revolutionize the way that companies bring novel neurotechnologies and smart MedTech devices to market.
| From: Eric Kikkert
CHESAPEAKE, Va., May 19, 2023 (SEND2PRESS NEWSWIRE) — A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: “The Slammer Method: How to create effective vaccines.” It recently appeared in the “Journal of Infectious Diseases and Therapy” and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.
| From: Neurotech Reports
NEW YORK, N.Y., March 7, 2023 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Sixth Annual Bioelectronic Medicine Forum will take place on April 4, 2023. The one-day event will be held at the New York Academy of Medicine in Manhattan.
| From: BioBuilder Educational Foundation
NEWTON, Mass., Jan. 24, 2023 (SEND2PRESS NEWSWIRE) — The BioBuilder Educational Foundation, Inc. (“BioBuilder”), which has a decade of empowering teachers and schools to bring synthetic biology education to school districts in 47 states, today announced its launch of a strategic planning process designed to grow the bioeconomy workforce at scale in urban, rural, and tribal communities.
| From: BioBuilder Educational Foundation
BOSTON, Mass., Nov. 18, 2022 (SEND2PRESS NEWSWIRE) — As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.
| From: SottoPelle Therapy
SCOTTSDALE, Ariz., Oct. 18, 2022 (SEND2PRESS NEWSWIRE) — Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies’ innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).
| From: SottoPelle Therapy
SCOTTSDALE, Ariz., Sept. 28, 2022 (SEND2PRESS NEWSWIRE) — Dosaggio™ by SottoPelle® and Cerbo announced today that they have entered into a partnership that integrates the two companies’ innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).
| From: BioBuilder Educational Foundation
BOSTON, Mass., Sept. 20, 2022 (SEND2PRESS NEWSWIRE) — Thanks to a two-year grant recently awarded by BioMADE, the BioBuilder Educational Foundation will expand a program that has supported thousands of high school inventors over the last decade. BioBuilder is leading the project, “Launching High School Bioengineers on their Paths to College and Careers,” with funding that will bring the authentic tools and approaches for engineering biology to BioBuilderClub students nationwide in collaboration with East Tennessee State University, Ars Biotechnica, and Daicel Arbor Biosciences.
| From: ARCHIVAL PRESS RELEASES
AUSTIN, Texas, Sept. 13, 2022 (SEND2PRESS NEWSWIRE) — Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.
| From: Proteios Technology Inc.
SEATTLE, Wash., Sept. 8, 2022 (SEND2PRESS NEWSWIRE) — Proteios Technology, Inc. is pleased to announce it’s received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios’ cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.
| From: ARCHIVAL PRESS RELEASES
AUSTIN, Texas, April 29, 2022 (SEND2PRESS NEWSWIRE) — Kalyagen® is pleased to announce that it will be attending the Fort Lauderdale Open as part of its sponsorship of golf professional Jerrel Gill. The Open will be hosted at the Fort Lauderdale Country Club on May 2-3, 2022.
| From: ARCHIVAL PRESS RELEASES
AUSTIN, Texas, April 27, 2022 (SEND2PRESS NEWSWIRE) — Kalyagen is pleased to announce that it will be attending and hosting a booth (#121) at the upcoming Paleo f(x)™ 2022 conference to be held in Austin on April 29 – May 1. STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
| From: Vyriad Inc.
ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.
| From: Pure MHC LLC
OKLAHOMA CITY, Okla., AUSTIN, Texas and MELBOURNE, Australia, April 6, 2022 (SEND2PRESS NEWSWIRE) — Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.
| From: Neurosoft Bioelectronics
GENEVA, Switzerland, and NEW YORK, N.Y., April 5, 2022 (SEND2PRESS NEWSWIRE) — Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.
| From: Neurotech Reports
NEW YORK, N.Y., March 28, 2022 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that founders and CEOs of several promising bioelectronic medicine startups will present at the Fifth Annual Bioelectric Medicine Forum on April 5, 2022. The event will take place in New York City, although participation via Zoom videoconference will be accommodated.
| From: ARCHIVAL PRESS RELEASES
AUSTIN, Texas, March 10, 2022 (SEND2PRESS NEWSWIRE) — Kalyagen® is pleased to announce that it is a supporting partner of two upcoming South Florida PGA Section events and golf professional Jerrel Gill. The two events are the South Florida PGA Foundation PGA HOPE Classic on May 12, 2022 and the South Florida Open on June 21-23, 2022.
| From: Pure Transplant Solutions LLC
AUSTIN, Texas and BARCELONA, Spain, Feb. 15, 2022 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d’Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.
| From: Pure Transplant Solutions LLC
AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D.
| From: Neurotech Reports
SAN FRANCISCO, Calif., Nov. 8, 2021 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the San Francisco, California publisher of market intelligence for the healthcare industry, announced the launch of a new monthly newsletter covering the bioelectronic medicine industry, one of the newest and fastest growing industry segments. The publication, BioElectRx Business Report, is the first industry newsletter devoted to bioelectronic medicine.
| From: ARCHIVAL PRESS RELEASES
AUSTIN, Texas, Oct. 12, 2021 (SEND2PRESS NEWSWIRE) — Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau’s, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.
| From: ICell Gene Therapeutics LLC
STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.
| From: Vyriad Inc.
ROCHESTER, Minn., Aug. 24, 2021 (SEND2PRESS NEWSWIRE) — Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company’s board of directors.
| From: KROST CPAs and Consultants
LOS ANGELES, Calif., Aug. 11, 2021 (SEND2PRESS NEWSWIRE) — Integrity Bio, Inc., a privately held formulation and fill-finish organization, was sold to Curia (formerly Albany Molecular Research, Inc. (AMRI)), a Contract Development and Manufacturing Organization (CDMO) and leading global provider of advanced contract research, development, and manufacturing solutions. KROST, a Los Angeles-based firm, acted as the exclusive financial advisor to Integrity Bio in the transaction.
| From: Pure Transplant Solutions LLC
AUSTIN, Texas and CAMBRIDGE, U.K., July 21, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke’s Hospital.
| From: BioAustinCTX
AUSTIN, Texas, June 3, 2021 (SEND2PRESS NEWSWIRE) — Life Science industry organization BioAustin today announced changes to its leadership team, brand positioning, and long-term strategy focused on facilitating the continued growth of the life science industry in Central Texas. Over the past several years, Austin and the Central Texas region have developed into one of the fastest-growing life science hubs in the U.S.
